| 词条 | Emibetuzumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = zu/o | target = HGFR | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1365287-97-3 | ATC_prefix = none | ATC_suffix = | PubChem = | IUPHAR_ligand = 7748 | DrugBank = | ChemSpiderID = none | C=6356 | H=9810 | N=1694 | O=2014 | S=48 | molecular_weight = 143.7 kg/mol | synonyms = LY2875358 }}Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3] This drug was developed by Eli Lilly & Company. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 | journal = WHO Drug Information | volume = 28 | issue = 2 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for tumors}}{{Growth factor receptor modulators}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association. 3. ^http://meetinglibrary.asco.org/content/164953-176 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。